5 results
diagnosis apml chemotherapy cyp3a4 differentiation doac hemolyticuremicsyndrome hus inducers inhibitors interactions management mds microangiopathy myelodysplasia myelodysplastic pglycoprotein purpura reactions syndrome
Thrombotic Microangiopathy - TTP VS HUS Big picture points : Often hard to differentiate the two entities,
Often hard to differentiate ... and first-line treatment ... thrombocytopenia #Comparison ... #Diagnosis #Table ... #Hematology
TRALI vs TACO - Transfusion Reactions TRALI: • Epidemiology: 0.1% of transfused patientsl • Risk factors: Critical
: 33% • Treatment ... : Age>60, CKD, CHF ... Transfusion #Reactions #hematology ... #diagnosis #comparison ... #table
Differentiation Syndrome in APML Epidemiology: • Incidence: common in APL (2-48% depending on the study) • Triggers:
Triggers: ATRA treatment ... initiation • Differential ... sepsis), PE, DAH, CHF ... diagnosis #management #hematology ... #oncology
(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓) of cytochrome p450 CYP3A4 and P-glycoprotein. DOACs are substrates
interactions) Cancer-treatment ... #Chemotherapy #Oncology ... #Hematology #Interactions ... #Table #Pharmacology
Myelodysplastic Syndromes (MDS) What? Myelodysplastic syndromes are a group of disorders caused by blood cells that are poorly
factor (GCSF) treatments ... blood count with differential ... factors (examples: G-CSF ... Syndromes #diagnosis #hematology ... #oncology
No results found for "HFrEF chf treatment hematology table pharmacology comparison differential hepatology oncology apml"
Try removing search terms or sorting by relevance
Or Upload an image for you and others searching for #HFrEF #chf #treatment #hematology #table #pharmacology #comparison #differential #hepatology #oncology #apml